Cardiorenalmetabolic

Although new guidelines call for universal screening, most Americans with elevated Lp(a) still don't know their number.

All from July, these 5 novel therapeutics each claimed a “first” in their category.

Katherine Wilemon, Family Heart Foundation, described the biggest unmet need when it comes to public awareness of Lp(a) and its associated risk factors.

A new AHA scientific statement defines pediatric cardiogenic shock and proposes a 5-stage classification to guide diagnosis, monitoring, and escalation of care.

Researchers found no evidence that cooling beyond 6 hours at 33°C improved neurological outcomes in comatose survivors of out-of-hospital cardiac arrest.

A study of more than 270,000 patients with HF found a U-shaped link between ventricular size and mortality risk.

Katherine Wilemon of the Family Heart Foundation discusses the need for Lp(a) screening in the US, where rates are historically low despite risk.

An FDA committee voted 9-3 that available data did not provide substantial evidence of effectiveness for deramiocel in DMD.

Acoramidis attenuated declines in patient-reported health status through 30 months, complementing previously reported survival and hospitalization benefits.

A target trial emulation found GLP-1 RA initiation was associated with a 21% lower 3-year fragility fracture risk compared with DPP-4 inhibitor therapy.

A new analysis finds up to a 98.8% probability that liberal transfusion lowers 30-day death or myocardial infarction risk vs restrictive care.

Clinicians say workflow changes, not education alone, are closing screening and treatment gaps in cardio-kidney-metabolic (CKM) care.

The autoinjector delivers subcutaneous furosemide with IV-equivalent exposure in under 10 seconds for adults with heart failure or CKD-related edema.

Eplontersen added to standard of care did not significantly reduce cardiovascular death and recurrent events, a study finds.

A digitally enabled quality improvement strategy lowered LDL-C and boosted treatment intensification, though most patients still missed guideline targets.

Left atrial (LA) strain impairment in dilated cardiomyopathy was driven by ventricular dilation, not left bundle branch block.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, explains how GLP-1-based therapies are reshaping diabetes, obesity, and cardiometabolic care and what that means for coverage decisions.

An analysis found no significant differences in care escalation, readmission, mortality, or guideline-directed therapy use between home-based and inpatient care.

Commercial cardiology prices vary widely by insurer and state, with facility fees for procedures like ICD implantation differing more than 5-fold.

In trials, the first oral PCSK9 inhibitor cut LDL cholesterol by up to 60%, which matched the efficacy of injectable PCSK9 therapies.

Two studies identify molecular targets that could help preserve insulin-producing cell function.

A study finds that 1- and 3-month dual antiplatelet therapy reduces bleeding vs standard regimens in patients at high bleeding risk.

Vera's atacicept (Trutakna) wins FDA accelerated approval after a 46% proteinuria drop in the ORIGIN 3 trial.

A UK Biobank analysis found that IL-6, but not hsCRP, modified the association between elevated lipoprotein(a) and coronary artery disease risk.

A retrospective cohort study found stable blood pressure alongside significant reductions in LVOT gradients, regardless of hypertension status.